Targeting human mast cells expressing G-protein-coupled receptors in allergic diseases

Allergology International

Volumn 57, Issue 3, 2008, Pages 197-203

  Okayama, Yoshimichi ^a   Saito, Hirohisa ^b   Rai, Chisei ^a  

^a NIHON UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Allergic diseases; Bronchial asthma; GPCRs; Human mast cells; Urticaria

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CELL PROTEIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 34; HISTAMINE; HISTAMINE H4 RECEPTOR; LIGAND; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 3; MAS RELATED GENE X1 PROTEIN; MAS RELATED GENE X2 PROTEIN; NEUROPEPTIDE; PEPTIDOLEUKOTRIENE RECEPTOR 1; PEPTIDOLEUKOTRIENE RECEPTOR 2; PURINERGIC P2Y1 RECEPTOR; PURINERGIC RECEPTOR; RECEPTOR PROTEIN; SOMATOSTATIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; SUBSTANCE P; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALLERGY; ASTHMA; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; CELL SECRETION; DRUG TARGETING; EVIDENCE BASED MEDICINE; HUMAN; HUMAN MAST CELL; MAST CELL; MAST CELL DEGRANULATION; MICROENVIRONMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; URTICARIA;

EID: 53749086028     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.R-08-163     Document Type: Review

References (60)

1. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006;6:218-30.
2. Hernanz A, Muelas G, Borbujo J. Plasma neuropeptide pattern in acute idiopathic urticaria. Int Arch Allergy Appl Immunol 1989; 90:198-200.
3. Lowman MA, Benyon RC, Church MK. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol 1988;95:121-30.
4. Kuehn HS, Gilfillan AM. G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett 2007; 113:59-69.
5. Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 1993;148:91-7.
6. Csoma Z, Huszar E, Vizi E et al. Adenosine level in exhaled breath increases during exercise-induced bronchoconstriction. Eur Respir J 2005;25:873-8.
7. Ammit AL Hastie AT, Edsall LC et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. Faseb J2001; 15:1212-4.
8. Munakata M. Airway remodeling and airway smooth muscle in asthma. Allergol Int 2006;55:235-43.
9. Okayama Y, Ra C, Saito H. Role of mast cells in airway remodeling. Curr Opin Immunol 2007;19:687-93.
10. Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992;97:216-25.
11. Bissonnette EY, Befus AD. Anti-inflammatory effect of beta 2-agonists: inhibition of TNF-alpha release from human mast cells. J Allergy Clin Immunol 1997;100:825-31.
12. Wang XS, Lau HY. Beta-adrenoceptor-mediated inhibition of mediator release from human peripheral blood-derived mast cells. Clin Exp Pharmacol Physiol 2006;33:746-50.
13. Akabane H, Murata M, Kubota M et al. Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells. Allergol Int 2006;55:387-93.
14. Urban JD, Clarke WP, von Zastrow M et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320:1-13.
15. Baker JG, Hill SJ. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 2007;28:374-81.
16. Tedeschi A, Lorini M, Asero R. No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. Clin Exp Dermatol 2005; 30:171-5.
17. Tatemoto K, Nozaki Y, Tsuda R et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006;349:1322-8.
18. Dong Y, Han S, Zylka MJ, Simon MI, Anderson VJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001;106:619-32.
19. Lembo PM, Grazzini E, Groblewski T et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 2002;5: 201-9.
20. Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem 2003; 278:44400-4.
21. Gerard NP, Gerard C. Complement in allergy and asthma. Curr Opin Immunol 2002;14:705-8.
22. Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002;109:114-8.
23. Church MK, Clough GF. Human skin mast cells: in vitro and in vivo studies. Ann Allergy Asthma Immunol 1999; 83:471-5.
24. Wojta J, Kaun C, Zorn G et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002;100:517-23.
25. Thangam EB, Venkatesha RT, Zaidi AK et al. Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. Faseb J 2005;19: 798-800.
26. Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 2005;42:581-7.
27. Feng C, Mery AG, Beller EM, Favot C, Boyce JA. Adenine nucleotides inhibit cytokine generation by human mast cells through a Gs-coupled receptor. J Immunol 2004;173:7539-47.
28. Sugo T, Tachimoto H, Chikatsu T et al. Identification of a lysophosphatidylserine receptor on mast cells. Biochem Biophys Res Commun 2006;341:1078-87.
29. Polosa R, Ng WH, Crimi N et al. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 1995;151: 624-9.
30. Polosa R. Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur Respir J 2002;20:488-96.
31. Bochenek G, Nizankowska E, Gielicz A, Szczeklik A. Mast cell activation after adenosine inhalation challenge in patients with bronchial asthma. Allergy 2008;63:140-1.
32. Crummy F, Livingston M, Ennis M, Heaney LG. Mast cell mediator release in nonasthmatic subjects after endobronchial adenosine challenge. J Allete Clin Immunol 2004;114:34-9.
33. Zhong H, Shlykov SG, Molina JG et al. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol 2003; 171:338-45.
34. Feoktistov I, Polosa P, Holgate ST, Biaggioni I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacal Sci 1998;19:148-53.
35. Peters SP, Schulman ES, Schleirner RP, MacGlashan DW Jr, Newball HH, Lichtenstein LM. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. Am Rev Respir Dis 1982; 126:1034-9.
36. Schulman ES, MacGlashan DW Jr, Peters SP, Schleimer RP, Newball HH, Lichtenstein L.M. Human lung mast cells: purification and characterization. J Immunol 1982; 129:2662-7.
37. Hughes PJ, Holgate ST, Church MK Adenosine inhibits and potentiates IgE-dependent histamme release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol 1984; 33:3847-52.
38. Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G. Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 1988; 138:1143-51.
39. Peachell PT, Lichtenstein LM, Schleimer RP. Differential regulation of human basophil and lung mast cell function by adenosine. J Pharmacol Exp Ther 1991;256:717-26.
40. Suzuki H, Takei M, Nakahata T, Fukamachi H. Inhibitory effect of adenosine on degranulation of human cultured mast cells upon cross-linking of Fc epsilon RI. Biochem Biophys Res Commun 1998; 242:697-702.
41. Feoktistov I, Garland EM, Goldstein AE et al. Inhibition of human mast cell activation with the novel selective adenosine A (2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX) (2). Biochem Pharmacol 2001;62:1163-73.
42. Schulman ES, Glaum MC, Post T et al. ATP modulates anti IgE-mduced release of histamme from human lung mast cells. Am J Respir Cell Mol Biol 1999;20:530-7.
43. Duffy SM, Cruse G, Brightling CE, Bradding P. Adenosine closes the K + channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur J Immunol 2007;37:1653-62.
44. Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y. Sphingosine 1-phosphate: synthesis and release. Prostaglandins 2001; 64:107-22.
45. Ancellin N, Colmont C, Su J et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002; 277:6667-75.
46. Pappu P, Schwab SF, Cornelissen I et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316: 295-8.
47. Jolly PS, Bektas M, Olivera A et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004;199:959-70.
48. Spiegel S, Milstien S. Functions of a new family of sphingosine-1-phosphate receptors. Biochim Biophys Acta 2000; 1484:107-16.
49. Oskeritzian CA, Milstien S, Spiegel S. Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacol Ther 2007; 115:390-9.
50. Deshpande DA, Penn RB. Targeting G protein-coupled receptor signaling in asthma. Cell Signal 2006;18:2105-20.
51. Oskeritzian CA, Alvarez SE, Hait NC, Price MM, Milstien S, Spiegel S. Distinct roles of sphingosine kinases 1 and 2 in human mast cell functions. Blood 2008;111:4193-200.
52. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-705.
53. Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879-85.
54. Chen FH, Samson Kr, Nliura K et al. Airway remodeling: a comparison between fatal and nonfatal asthma. J Asthma 2004; 41:631-8.
55. Brightling CE, Ammit AJ, Kaur D et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 2005;171:1103-8.
56. El-Shazly A, Berger P, Girodet PO et al. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J Immunol 2006;176:1860-8.
57. Godot V, Arock M, Garcia G et al. H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J Allergy Clin Immunol 2007;120:827-34.
58. Jiang Y, Kanaoka Y, Feng C, Nocka K, Rao S, Boyce JA. Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/ intracrine cysteinyl leukotriene-induced signaling. J Immunol 2006;177:2755-9.
59. Jiang Y, Borrelli LA Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; 110:3263-70.
60. Lin DA, Boyce JA. IL-4 regulates MEK expression required for lysophosphatidic acid-mediated chemokine generation by human mast cells. J Immunol 2005;175: 5430-8.